Global Biological Safety Testing Market Outlook
The global biological safety testing market size was valued at USD 4.53 billion in 2023, driven by innovation of testing technologies across the globe. The market size is anticipated to grow at a CAGR of 13.2% during the forecast period of 2024-2032 to achieve a value of USD 20.03 billion by 2032.Biological Safety Testing: Introduction
Biological safety testing is a crucial process in the biopharmaceutical industry, ensuring that products such as vaccines, therapeutics, and medical devices are free from harmful contaminants like bacteria, viruses, and toxins. This testing involves a series of rigorous procedures, including sterility tests, endotoxin analyses, and mycoplasma detection, aimed at verifying product safety and compliance with regulatory standards. It's essential for protecting patient health and maintaining the integrity and quality of biomedical products.Key Trends in the Global Biological Safety Testing Market
There's a growing emphasis on regulatory compliance across the globe, leading to more stringent safety testing requirements for biopharmaceutical products. This trend is driving the demand for biological safety testing services.Innovations in testing technologies, such as rapid microbiological methods (RMM) and high-throughput screening, are enhancing the efficiency and accuracy of biological safety testing.
The increasing production of biologics, including vaccines, monoclonal antibodies, and cell and gene therapies, is driving the need for comprehensive safety testing to ensure product quality and patient safety.
Many biopharmaceutical companies are outsourcing safety testing to specialized laboratories to reduce costs and leverage technical expertise, leading to the growth of the contract testing market.
Events like the COVID-19 pandemic have highlighted the importance of ensuring biological safety, leading to increased investment in safety testing for vaccines and therapeutics.
Global Biological Safety Testing Market Segmentation
Market Breakup by Product Type
- Reagents and Kits
- Instruments
- Other Products
Market Breakup by Test
- Sterility Tests
- Bioburden Tests
- Endotoxin Tests
- Other Tests
Market Breakup by Application
- Vaccines and Therapeutics
- Cellular and Gene Therapy
- Blood and Blood-Based Therapy
- Other Applications
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Biological Safety Testing Market Overview
North America is likely to dominate the market due to stringent regulatory standards, a well-established biopharmaceutical industry, and significant investment in research and development. The United States, in particular, is a hub for innovation in biological safety testing technologies.Europe shows strong growth, driven by robust healthcare systems, comprehensive regulatory frameworks, and a focus on maintaining high safety standards for pharmaceuticals and medical devices. Countries like Germany, the UK, and France are key contributors.
Asia-Pacific experiences rapid growth due to increasing investment in healthcare, rising demand for biopharmaceutical products, and improving regulatory landscapes. Countries like China, Japan, and India are investing heavily in healthcare infrastructure and research, contributing to market growth.
Latin America is an emerging market with growing potential, driven by improvements in healthcare infrastructure, rising investment in the biopharmaceutical sector, and increasing awareness about product safety and quality.
Middle East & Africa shows gradual growth, influenced by increasing investment in healthcare infrastructure, efforts to standardize regulatory frameworks, and a rising focus on healthcare quality and safety.
Global Biological Safety Testing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The Avance Biosciences- Avance Biosciences
- Cytovance Biologics
- Eurofins Scientific
- Lonza
- Merck KGaA
- Promega Corporation
- Thermo Fisher Scientific
- Toxikon
- WuXi AppTec
- Biomerieux SA
- Nelson Laboratories, LLC
- Almac Group
- GenScript
- InvivoGen
- Maravai LifeSciences
This product will be delivered within 5-7 business days.
Table of Contents
1 Preface
3 Global Biological Safety Testing Market Overview
4 Global Biological Safety Testing Market Landscape
5 Global Biological Safety Testing Market Dynamics
6 Global Biological Safety Testing Market Segmentation
7 North America Biological Safety Testing Market
8 Europe Biological Safety Testing Market
9 Asia Pacific Biological Safety Testing Market
10 Latin America Biological Safety Testing Market
11 Middle East and Africa Biological Safety Testing Market
12 Patent Analysis
13 Grants Analysis
14 Funding Analysis
15 Partnership and Collaborations Analysis
16 Regulatory Framework
17 Supplier Landscape
18 Global Biological Safety Testing Market - Distribution Model (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
21 Payment Methods (Additional Insight)
Companies Mentioned
- Avance Biosciences
- Cytovance Biologics
- Eurofins Scientific
- Lonza
- Merck KGaA
- Promega Corporation
- Thermo Fisher Scientific
- Toxikon
- WuXi AppTec
- Biomerieux SA
- Nelson Laboratories LLC
- Almac Group
- GenScript
- InvivoGen
- Maravai LifeSciences
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 160 |
Published | February 2024 |
Forecast Period | 2024 - 2032 |
Estimated Market Value ( USD | $ 7.4 Billion |
Forecasted Market Value ( USD | $ 20 Billion |
Compound Annual Growth Rate | 13.2% |
Regions Covered | Global |
No. of Companies Mentioned | 15 |